ArticleTherapeutic advances in medical oncology2021
Real-life prognosis of 5041 bone-only metastatic breast cancer patients in the multicenter national observational ESME program.
Article in Therapeutic advances in medical oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03275311 (Epidemiological Strategy and Medical Economic), which is not on this map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Epidemiological Strategy and Medical Economic (ESME) Research Program / Academic Real World Database: Evolution of the Therapeutic Care in Metastatic Breast Cancer Across the French Comprehensive Cancer Centers From 2008
Who cites it
19 citing papers in PubMed.
- The prognosis of breast cancer patients with bone metastasis could be potentially estimated based on blood routine test and biochemical examination at admission.Annals of medicine · 2023Trial
- Article
- Curative-intent tri-modality treatment of de novo bone-only oligometastatic breast cancer: single-center patient outcomes.BMC cancer · 2026Article
- Management of Bone-Only Progressive Disease in Metastatic Breast Cancer-A Retrospective Single-Center Analysis.Journal of clinical medicine · 2026Article
- Real-world effectiveness of palbociclib in combination with an aromatase inhibitor in HR+/HER2- bone-only metastatic breast cancer.Breast (Edinburgh, Scotland) · 2026Article
- Metastatic breast cancer outcome in a real-world setting: analysis for long-term survival and curability in a prospective dataset.The oncologist · 2026Article
- Defining prognostic subgroups and treatment outcomes in estrogen receptor low-positive de novo metastatic breast cancer.Breast cancer research and treatment · 2026Observational
- Article
- Fluoroestradiol (FES) and Fluorodeoxyglucose (FDG) PET imaging in patients with ER+, HER2-positive or HER2-negative metastatic breast cancer.Breast cancer research : BCR · 2025Article
- Article
- A Representative Clinical Course of Progression, with Molecular Insights, of Hormone Receptor-Positive, HER2-Negative Bone Metastatic Breast Cancer.International journal of molecular sciences · 2024Review
- Abemaciclib, Palbociclib, and Ribociclib in Real-World Data: A Direct Comparison of First-Line Treatment for Endocrine-Receptor-Positive Metastatic Breast Cancer.International journal of molecular sciences · 2023Article
- Article
- Management of Oligometastatic Breast Cancer: An Expert Committee's Opinion.Current oncology (Toronto, Ont.) · 2023Article
- Gene expression in metastatic breast cancer-patterns in primary tumors and metastatic tissue with prognostic potential.Frontiers in molecular biosciences · 2023Article
- Advances in lipid-based nanocarriers for breast cancer metastasis treatment.Frontiers in medical technology · 2022Review
- Clinical Characteristics, Prognostic Factors and Treatment Outcomes of Patients with Bone-Only Metastatic Breast Cancer.Cancer management and research · 2022Article
- Selected Patients With Peritoneal Metastases From Breast Cancer May Benefit From Cytoreductive Surgery: The Results of a Multicenter Survey.Frontiers in oncology · 2022Article
- Prognostic factors and survival prediction in HER2-positive breast cancer with bone metastases: A retrospective cohort study.Cancer medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBone-only (BO) metastatic breast cancer (MBC) is considered a more favorable entity than other MBC presentations. However, only few retrospective series and data from selected randomized controlled trials have been reported so far.
methodsUsing the French national multicenter ESME (Epidemiological Strategy and Medico Economics) Data Platform, the primary objective of our study was to compare the overall survival (OS) of patients with BO
resultsOut of 20,095 eligible women, 5041 (22.4%) patients had BO disease [hormone-receptor positive (HR+)/human epidermal growth-factor-receptor-2 negative (HER2-),
conclusionBO MBC patients have better outcomes compared with non-BO MBC, consistently, through all MBC subtypes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.